The antiphospholipid syndrome was initially described in 1986. To reassess the validity of antiphospholipid antibodies in systemic lupus erythematosus (SLE) 
profile was analysed and correlated with clinical findings such as thrombosis, abortions, or thrombocytopenia. A low prevalence of these antibodies was found (13 patients; 14%) with a high specificity for thrombosis (92%) and abortions (92%).
The importance ofanticardiolipin antibodies as a risk factor for thrombosis or abortions, or both, in patients with SLE is reaffirmed by this work.
Work carried out over the past few years has led to the definition of the antiphospholipid syndrome as the association of thrombosis, recurrent abortion, and thrombocytopenia with anticardiolipin antibodies and/or the detection of lupus anticoagulant activity in the patient's plasma.'
Initial work on this subject showed a high incidence (36-60%) of anticardiolipin antibodies in patients with systemic lupus erythematosus (SLE) and confirmed the association of the clinical and laboratory findings defined in the antiphospholipid syndrome.7 '9 To assess the validity of the definition more than five years after the initial description of this syndrome, we decided to study our own population of patients with SLE and to determine the prevalence of anticardiolipin antibodies and their correlation with thrombosis, abortions, and thrombocytopenia. In addition, when we tested the specificity, we found that of the remaining 77 patients without thrombosis, 71 had no anticardiolipin antibodies (specificity 92%). Twenty one patients (22%) had had recurrent abortions. The incidence of these events was also significantly higher among patients with anticardiolipin antibodies (7/13; 54%) than among those without (14/80; 18%) (p<0-01). When we tested the sensitivity of anticardiolipin antibodies for recurrent abortions, we found that of the 21 patients who had had abortions, seven had anticardiolipin antibodies (sensitivity 33%). In addition, when we tested the specificity, we found that of the remaining 72 patients without recurrent abortions, 68 had no anticardiolipin antibodies (specificity 92%).
Twelve patients (13%) had thrombocytopenia, but no association with the presence of anticardiolipin antibodies was found.
Discussion
In this series of patients, levels of IgG anticardiolipin antibodies were strongly associated with thrombosis and abortions. This reinforces previous findings stressing such an association.4 Although the time between the events and the determinations of the anticardiolipin antibody titres was variable in our study, the finding of this association is of great importance. As noted by Harris, patients with IgG anticardiolipin antibodies who have had thrombosis or abortions are at a higher risk for developing such clinical events in the future. 14 15 On the other hand, the IgM isotype seems to be less specific for the antiphospholipid syndrome.
The overall prevalence of anticardiolipin antibodies was only 14%. The reported prevalence of anticardiolipin antibodies in patients with SLE has varied widely. '6 This variability is almost certainly due to the cut off positive level and to patient selection. In this ELISA only values exceeding five GPL or 3-2 MPL units were considered positive. This corresponds to five standard deviations (SD) above that of the normal population. In a large number of published reports, results of two SD above normal are considered positive. In early studies carried out in our laboratory a prevalence of 61% was found using a cut off for positivity of 2-97 SD.2 Thus the rigidity of our standardised ELISA for anticardiolipin antibodies might explain in part the low incidence of anticardiolipin antibodies in this group of patients. Another factor that might have influenced our results is that all patients were receiving some treatment by the time their blood was collected for analysis. '7 As a result of the association of thrombocytopenia with increased levels of anticardiolipin antibodies in some patients with SLE, '8 Although the mechanism of action of antiphospholipid antibodies is still unclear, the presence of these antibodies should be considered a risk factor for thrombosis and abortions in patients with SLE. 
